Zhu Y, et al. - Among consecutively selected ST-segmental elevation myocardial infarction (STEMI) patients who had undergone a successful primary percutaneous coronary intervention (n=87), researchers assessed the serial change in serum monocyte chemoattractant protein-1 (MCP-1) as well as the link between the time course of serum MCP-1 and early changes in myocardial function. Two subgroups were defined based on the median value of MCP-1 upon admission. They defined an early change in left ventricular ejection fraction (LVEF) as (LVEF at 3 months post-STEMI)-(LVEF at 2 days post-STEMI). Findings revealed a positive correlation of admission MCP-1 with hypersensitive cardiac troponin I (hs-cTnI) at different time points and peak hs-cTnI, and also an inverse association of admission MCP-1 with early improvements in myocardial function in patients with first STEMI. A promising therapeutic target in myocardial ischaemia/reperfusion injury might be suppression of the expression of MCP-1.